---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-23-000030"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2023-04-28T23:59:59+00:00"
generated_at: "2026-06-16T06:40:33.492617+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GeneDx announces 1-for-33 reverse stock split effective May 4, 2023; two directors not standing for re-election

## Summary
- Reverse stock split at 1-for-33 ratio approved by Board on April 24, 2023; effective May 4, 2023.
- No fractional shares issued; any fractional share rounded up to nearest whole share.
- CUSIP changes: common stock to 81663L 200; public warrants to 81663L 127.
- Directors Rachel Sherman and Dennis Charney will not stand for re-election at 2023 annual meeting; no disagreement.
- Warrant exercise price adjusted from $11.50 to $379.50 per share; each warrant now exercisable for 1/33 of a share.

## SEC filing metadata
- accession: 0001818331-23-000030
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2023-04-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 3.03, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000030/0001818331-23-000030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000030/smfr-20230424.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-23-000030
- JSON: https://secwatch.observer/filing/0001818331-23-000030.json
- Plain text: https://secwatch.observer/filing/0001818331-23-000030.txt

## Key facts
- Executive change
  Rachel Sherman departed as Director at GeneDx Holdings Corp..
  - Action: will not stand for re-election
  - Role: Director
  source text: On April 24, 2023, Rachel Sherman and Dennis Charney notified the Board that they will not stand for re-election as directors of the Company at the Company’s 2023 annual meeting of stockholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000030/0001818331-23-000030-index.htm
- Executive change
  Dennis Charney departed as Director at GeneDx Holdings Corp..
  - Action: will not stand for re-election
  - Role: Director
  source text: On April 24, 2023, Rachel Sherman and Dennis Charney notified the Board that they will not stand for re-election as directors of the Company at the Company’s 2023 annual meeting of stockholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000030/0001818331-23-000030-index.htm
- Governance Changes
  GeneDx Holdings Corp.: Certificate of Amendment to effect a 1-for-33 reverse stock split of Class A Common Stock, approved by board on April 24, 2023 and filed on April 28, 2023 (effective 2023-05-04).
  - Change: charter amendment
  - Effective: 2023-05-04
  source text: On April 28, 2023, the Company filed a Certificate of Amendment (the “Reverse Stock Split Certificate of Amendment”) to the Charter with the Secretary of State of the State of Delaware to effect the Reverse Stock Split, effective as of May 4, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1818331/000181833123000030/0001818331-23-000030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.